Panel experts examine considerations for BTKi-based strategies in R/R CLL, highlighting pivotal findings from head-to-head trials, including acalabrutinib vs ibrutinib in ELEVATE-RR and zanubrutinib vs ibrutinib in ALPINE, covering safety, quality of life, and extended follow-up data.
Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma
Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth
HPV Vaccinations Associated With Lower Rates of HPV-Caused Cancers in Patients Under 40 Years of Age
AI Virtual Navigation May Reengage Patients to Undergo Missed Colonoscopies
2 Commerce Drive
Cranbury, NJ 08512